Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7213)	11/21/1999 8:20:00 PM
From: Ward Knutson	Read Replies (1) \| Respond to of 9719

47% is NOT the final number. "...non-small cell lung cancer experienced a 47% reduction in measurable tumor mass and remains in the study after more than six months of treatment..." - excerpt from MGI Pharma press release of last week. The patient, as you know is a Phase I and is still being treated after 6-months of therapy. Richard - 114 is continuing down a path which, if replicated, will ultimately prove your "Blitzer is a fool for not licensing the drug out long ago to protect Salagen profits" a tremendous error in judgement on your part. 114 is a toxin no doubt. Managing the toxicity is an issue with ALL chemo-agents, the Company has gone on record stating that the drug is being well tolerated in human clinical trials. Selective uptake is a key differentiator, you know of all the promise this unique mechanism has to offer I trust. Richard it strikes me that your distaste for Blitzer's style is clouding your view of what a tremendous impact 114 is likely to have both in the world of oncology and MGI Pharma's potential for explosive growth. Again I urge anyone interested to contact Bill Brown, certainly a broad & concurrent Phase III trial scenario would pressure the cash flow picture. They do appear to be working a plan which would bring expedited-review-approval, most likely in pancreatic, which would obviously generate greatly enhanced available cash-flow to fund a then expanded Phase III trial set. Remember once approved, the off-label sales of a promising & unique action chemo-agent are likely very significant. POINT: they don't need the Partner money until a broad Phase III is commenced, why do it until maximum return is at hand? Richard it appears you took Chuck's goals as unalterable promises. The evolution of MGI, and in particular his ability to maximize Salagen sales has enabled the postponement of inking that infamous (and at one time much needed) deal. This, in my well researched opinion, is in the best interests of shareholders. BTW, your free cash-flow calculations are inaccurate. I will provide a more detailed explanation on the SI-MOGN thread when time allows.